PG X CDS PROCESS OUTCOMES Tim Herr Northwestern University.

Slides:



Advertisements
Similar presentations
Taking Research and Development to the Clinic: Issues for Physicians AAAS/FDLI Colloquium I Diagnostics and Diagnoses Paths to Personalized Medicine Howard.
Advertisements

ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning” A Report of the American College of Cardiology Foundation Task Force on Clinical.
Web-based Application for Transfer-Discharge Medication Reconciliation Nick Honcharik, Pharm. D. Regional Pharmacy Manager WRHA.
Implementation of CYP2C19 Genotyping for Clopidogrel Gwen McMillin, PhD, DABCC (CC,TC) July 27, 2010.
Medication Reconciliation
Mark W Linder, Ph.D., DABCC, FACB Medical Director, EVP Operations Kristen K. Reynolds Ph.D. Associate Medical Director, VP Laboratory Operations Mark.
MSU HealthTeam Michigan State University WHAT’S NEW IN 9.2.
Physician Multidisciplinary Discharge Routine Training Guide June 2015.
Medication History: Keeping our patients safe. How do we get all of the correct details?
Electronic Data entry Using computers and the internet as the primary data entry and storage tool. Dr. Cindy McKeon, MD, MPH Weill Cornell Medical College.
Medication Reconciliation Veterans Affairs North Texas Health Care System March 2008.
Treatment Plan.
© VANDERBILT UNIVERSITY 2009 B I O M E D I C A L I N F O R M A T I C S A System to Improve Medication Safety in the Setting of Acute Kidney Injury Intervention.
The Antidote to Alert Fatigue May 26, 2010 Best Ever Medical Center Best City, IL MMI – 406: Decision Support Systems and Healthcare Suzi Birz, Nicki.
IF:Cardiovascular © PGXL Laboratories.
Coverage Indications, Limitations, and/or Medical Necessity This policy limits CYP2C19 (CPT 81225) and CYP2D6 (CPT 81226) genetic testing to defined indications.
Health Management Information Systems
A Director of Biomedical Informatics and Chief Operating Officer, UF Clinical and Translational Science Institute. b Chief Technology Officer, Department.
Personalized Medicine Dr. M. Jawad Hassan. Personalized Medicine Human Genome and SNPs What is personalized medicine? Pharmacogenetics Case study – warfarin.
PPIs reduces the antiplatelt effects of clopidogrel: According to a 2007 survey, clopidogrel is the sixth most commonly.
The Effect of Electronic Medical Record Alerts on Processes of Care Related to Preventing Falls in Community- Dwelling Elderly Patients David R. Goldmann.
Meditech 6x Pharmacy Medication Stock Charges. What is a Stock Charge? The Enter Stock Orders routine in Pharmacy allows you to enter the doses for medications.
PCI for STEMI Ari de la Hera, M.D..
Copyleft Clinical Trial Results. You Must Redistribute Slides The American College of Cardiology Foundation / American Heart Association Clopidogrel Recommendations.
Pharmacogenetics.
Configuring axiUm for Meaningful Use
Challenges to drug design Did you know? Over 2 million people are hospitalized each year for adverse reactions to prescription drugs. Over 2 million.
How Genetic Variants Impact the Safety and Effectiveness of Drugs Pharmacogenetics © PGXL Laboratories.
EHR Background Why EHRs? Improve Communication Improve Efficiency Save $$ Reduce Errors Take Better Care of Our Patients.
Does Clopidogrel Work In Every Person Cheap Clopidogrel Canadian Pharmacy inami plavix formulaire optimus trial clopidogrel what is the drug plavix used.
Pharmacogenomics: Improving the Dynamic of Care in Medication Management 1.
Rationale: A significant finding from the Joint Commission – when multiple medications are ordered to treat the same indication (e.g. Pain, Nausea, Constipation)
Clinical Documentation Pharmacy Department Dale Tucker, RPh, BCPS Harper University Hospital Hutzel Women’s Hospital Karmanos Cancer Hospital Rehabilitation.
Pharmacogenomics based personalized medicine: Are the standards of evidence requirements different from standards for Clinical-Based Personalized Medicine?
Generic Plavix 34 Image Cheap Plavix Canadian Pharmacy msds of clopidogrel bisulfate clopidogrel und operation plavix turns genertic should i take aspirin.
Date of download: 9/17/2016 From: Behavioral Therapy to Enable Women with Urge Incontinence to Discontinue Drug Treatment: A Randomized Trial Ann Intern.
GIFT: Genetics Informatics Trial of Warfarin
The Primary and Secondary Prevention of Cardiovascular Disease
PGx Logical Overview.
From: Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome Ann Intern Med. 2014;160(4): doi: /M
PhenGene P2Y12 Test.
HOW TO ENTER END OF TRIAL DATA
Pharmacogenomics Rita Leone, RN, MSN, CMSRN.
Prescription Decision Support For Primary Care
CYP2C19 Genotyping to Individualize Anti-platelet Therapy: Which one should we perform? How to interpret data? Is it ready for clinical practice? Alan.
Antiplatelet therapy for STEMI
Life after a Cardiovascular Event
From: United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications.
Drugs & Genetics: Why Do Some People Respond to Drugs Differently than Others? Bilal Mohammed.
Francesco Franchi, MD, Fabiana Rollini, MD, Jose Rivas Rios, MD, Andrea Rivas, MD, Malhar Agarwal, MD, Megha Kureti, MD, Deepa Nagaraju, MD, Mustafa Wali,
Pharmacy Use Case.
Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype status. Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype.
What is a PowerPlan? A PowerPlan is a care-planning tool that allows you to manage orders as they relate to a pre-defined plan of care. PowerPlans define.
Learning Objectives. Learning Objectives Variable Response to Clopidogrel.
11/12/2018 CYP2C19-Clopidogrel Development of these slides was supported by funding from the IGNITE Network. When using or adapting any of these slides.
11/12/2018 CYP2C19-Clopidogrel Development of these slides was supported by funding from the IGNITE Network. When using or adapting any of these slides.
Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.
A PRAGMATIC RANDOMIZED TRIAL OF CYP2C19 GENOTYPING IMPLEMENTATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (PCI) Sony Tuteja, PharmD, MS
PCP View: ACC/AHA Guidelines: Role of Moderate Intensity Statins
The Research Question How and why do primary care physicians (PCPs) use medications including antipsychotics, as well as non-pharmacologic strategies,
Relative Risk of Events by CHA2DS2-VASc Score
HOW TO ENTER END OF TRIAL DATA
Preemptive Pharmacogenomic Testing for Precision Medicine
What oral antiplatelet therapy would you choose?
Health Information Systems: Functional Capacity
Roberta Rossini et al. JCIN 2018;11:
Effect of VKORC1 Haplotype Combination on Clinical Warfarin Dose - Common haplotypes (H1, H2, H7, H8, and H9) were clustered with use of the UPGMA method.
The Case for Routine CYP2C19 ( Plavix® ) Genetic Testing
ESC Guideline on the Management of STEMI Recommendation for DAPT
Section C: Clinical trial update: Oral antiplatelet therapy
Presentation transcript:

PG X CDS PROCESS OUTCOMES Tim Herr Northwestern University

Goals Primary: Determine how PGx CDS alerts affect clinical action Intermediate: Inventory of alert scenarios across sites Understand rates at which alerts are firing Determine how physicians interact with alerts

Data Collection Data submission templates

Alert Scenarios

Example Alert Scenarios: Warfarin Marshfield: WARFARIN_2_2_AA “Genetic testing for this individual (CYP2C9*2/*2 and VKORC1: AA) indicates an initial Warfarin dose of 0.5 mg - 2 mg may be considered.” Mayo: warfarin/CYP2C9/VKORC1_dose_calculator “An alert/calculator is generated for new warfarin orders if patient has CYP2C9 and VKORC1 results in the EMR. The alert/calculator displays the variables used and the calculated dose.” Northwestern: Warfarin (Not on Medication, Prescribing) “Dosing calculator should be used to determine initial warfarin dose. Enter clinical data into dosing calculator for all patients. Addition of genetic information (see lab results) suggested for non- African Americans.”

Example Alert Scenarios: Clopidogrel Mt. Sinai: Clopidogrel-CYP2C19 IM “Change to either Prasugrel or Ticagrelor” Marshfield: CLOPIDOGREL_2_17 “Consider alternative antiplatelet therapy.” Northwestern: Clopidogrel Intermediate Metabolizer (Prescribing) “Consider alternative - medication may be ineffective if prescribed.”

Provider Information

Alert Instances

Alert Response vs. Clinical Response Accept Override Ignore Followed Not Followed No Action Alert Response Clinical Response

Alerts Submitted OrganizationNumber of Alerts Boston Children’s0 (No production alerts fired) Cincinnati Children’s22 Marshfield Clinic12 Mayo Clinic5 Mt. Sinai2 Northwestern36 (5 active; 31 passive) Vanderbilt143 Total220

Alerts by Drug-Gene Interaction

Alert Responses

Clinical Responses

Responses by DGI DGI# AlertsAcceptFollow clopidogrel simvastatin warfarin701

An Interesting Story… Alert: SIMVASTATIN METABOLISM- INTERMEDIATE ACTIVITY (NOT ON MED) Patient had been on simvastatin 40mg for several years but Rx was expired or discontinued Physician sees alert at order entry Physician opens SmartSet (informational materials) Physician orders simvastatin 40 mg, anyway

An Interesting Story… Approx. three weeks later... Alert: SIMVASTATIN METABOLISM- INTERMEDIATE ACTIVITY Physician #2 sees alert in General BPAs section Physician #2 opens SmartSet (informational materials) Physician #2 orders atorvastatin 20mg

Questions? Acknowledgements: The PGx Process Outcomes Workgroup Especially Luke Rasmussen and Josh Peterson